INNOVIVA, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
INNOVIVA, INC. (INVA) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$27.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-28.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2023-02-28
- INNOVIVA, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2020-09-30 was $2.00K.
- INNOVIVA, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2020-06-30 was -$35.00K, a 252.17% decline year-over-year.
- INNOVIVA, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2020-03-31 was $6.00K, a 53.85% decline year-over-year.
- INNOVIVA, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2019-09-30 was -$8.00K, a 214.29% decline year-over-year.
- INNOVIVA, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2020 was -$27.00K, a 190.00% decline from fiscal 2019.
- INNOVIVA, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2019 was $30.00K, a 100.00% increase from fiscal 2018.
- INNOVIVA, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2018 was $15.00K.
- INNOVIVA, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2017 was -$19.00K, a 733.33% decline from fiscal 2016.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$27.00K 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $2.00K 10-Q · filed 2021-10-27 | -$33.00K derived: sum of 2 quarters · filed 2021-10-27 | -$27.00K derived: sum of 3 quarters · filed 2021-10-27 | |
| 2020-06-30 | -$35.00K 10-Q · filed 2021-10-27 | -$29.00K derived: sum of 2 quarters · filed 2021-10-27 | ||
| 2020-03-31 | $6.00K 10-Q · filed 2021-10-27 | |||
| 2019-12-31 | $30.00K 10-K/A · filed 2022-03-17 | |||
| 2019-09-30 | -$8.00K 10-Q · filed 2020-10-28 | $15.00K derived: sum of 2 quarters · filed 2020-10-28 | $28.00K derived: sum of 3 quarters · filed 2020-10-28 | |
| 2019-06-30 | $23.00K 10-Q · filed 2020-10-28 | $36.00K derived: sum of 2 quarters · filed 2020-10-28 | ||
| 2019-03-31 | $13.00K 10-Q · filed 2020-10-28 | |||
| 2018-12-31 | $15.00K 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $7.00K 10-Q · filed 2019-10-30 | $19.00K derived: sum of 2 quarters · filed 2019-10-30 | $15.00K derived: sum of 3 quarters · filed 2019-10-30 | |
| 2018-06-30 | $12.00K 10-Q · filed 2019-10-30 | $8.00K derived: sum of 2 quarters · filed 2019-10-30 | ||
| 2018-03-31 | -$4.00K 10-Q · filed 2019-10-30 | |||
| 2017-12-31 | -$19.00K 10-K · filed 2020-02-19 | |||
| 2016-12-31 | $3.00K 10-K · filed 2019-02-19 | |||
| 2015-12-31 | $85.00K 10-K · filed 2018-02-23 | |||
| 2014-12-31 | -$249.00K 10-K · filed 2017-02-28 | |||
| 2013-12-31 | $63.00K 10-K · filed 2016-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |